Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Edwards Lifesciences Corp (EW)
Price$85.73Cached quote
Net income
2008
2009
2010
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | $2.05B | $1.90B | $1.68B | $1.45B | $1.32B | $1.24B |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | $1.53B | $1.41B | $1.19B | $1.04B | $922.3M | $818.1M |
| Gross margin | 78.01% | 79.46% | 80.47% | 83.79% | 76.13% | 75.36% | 74.37% | 74.77% | 74.52% | 73.09% | 75.25% | 73.07% | 74.74% | 74.15% | 70.82% | 71.78% | 69.80% | 66.10% |
| Research & development | $1.08B | $1.05B | $962.9M | $843.6M | $903.1M | $760.7M | $752.7M | $622.2M | $552.6M | $442.2M | $382.9M | $346.5M | $323.0M | $291.3M | $246.3M | $204.4M | $175.5M | $139.2M |
| Operating expenses | $3.47B | $2.94B | $2.72B | $2.24B | $2.29B | $2.41B | $2.09B | $2.04B | $1.47B | $1.42B | — | — | — | — | — | — | — | — |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $897.6M | $1.15B | $748.2M | $1.09B | $751.2M | — | — | — | — | — | — | — | — |
| Operating margin | 20.84% | 25.35% | 26.13% | 33.57% | 32.30% | 20.46% | 26.38% | 20.10% | 31.71% | 25.35% | — | — | — | — | — | — | — | — |
| EBITDA | $1.42B | $1.53B | $1.45B | $1.64B | $1.83B | $1.00B | $1.24B | $825.6M | $1.17B | $822.4M | — | — | — | — | — | — | — | — |
| EBITDA margin | 23.42% | 28.20% | 29.02% | 36.69% | 34.88% | 22.91% | 28.43% | 22.18% | 34.10% | 27.75% | — | — | — | — | — | — | — | — |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | — | — | — | — | — | — | — | — | — | — | $218.0M | $229.1M | $128.9M |
| Net profit margin | 17.69% | 76.75% | 27.99% | 34.09% | 28.73% | — | — | — | — | — | — | — | — | — | — | 15.07% | 17.34% | 10.41% |
| Basic EPSper basic share | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $0.31 | $0.30 | $0.26 | $0.42 | $0.19 | $0.28 | $0.23 | $0.21 | $0.23 | $0.13 |
| Diluted EPSper diluted share | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.30 | $0.29 | $0.25 | $0.42 | $0.19 | $0.27 | $0.22 | $0.20 | $0.22 | $0.12 |
Owners
Reported shareholders
10.20%of listed shares
BlackRock, Inc.58.79M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.20%58.79M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.52%37.62M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.58%26.41M shares |
STATE STREET CORP | 4.57%26.32M shares |
JPMORGAN CHASE & CO | 3.95%22.78M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.92%16.83M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.68%15.44M shares |
Bank of New York Mellon Corp | 2.44%14.08M shares |
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 2.26%13M shares |
Ninety One UK Ltd | 2.14%12.34M shares |
Aristotle Capital Management, LLC | 1.50%8.67M shares |
ALLIANCEBERNSTEIN L.P. | 1.50%8.66M shares |
FMR LLC | 1.46%8.44M shares |
NORGES BANK | 1.45%8.37M shares |
BROWN ADVISORY INC | 1.28%7.37M shares |
BANK OF AMERICA CORP /DE/ | 1.16%6.69M shares |
Artisan Partners Limited Partnership | 1.15%6.63M shares |
MORGAN STANLEY | 1.10%6.34M shares |
DEUTSCHE BANK AG\ | 0.99%5.71M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.98%5.68M shares |
Percentages use 576.6M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 30, 2026Form 4 · 10b5-1 | Lippis Daniel J.CVP, TAVR | SellCommon Stock | 619 | $91.40 | $56.6K | 40.4K |
| Jun 17, 2026Form 4 · 10b5-1 | Zovighian Bernard JCEO | SellCommon Stock · indirect | 523 | $87.92 | $46.0K | 11.5K |
| May 29, 2026Form 4 | Dahl Andrew M.SVP, Corporate Controller | SellCommon Stock | 567.53 | $86.08 | $48.9K | 15.3K |
| May 27, 2026Form 4 | BOBO DONALD E JRCVP,Strategy/Corp Development | SellCommon Stock · indirect | 23.1K | $86.42 | $2.00M | 98.6K |
| May 22, 2026Form 4 | Chopra DaveenCVP, TMTT & Surgical | SellCommon Stock | 1.5K | $84.60 | $126.9K | 44.3K |